Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings

Abstract Recently an increased echogenicity of the substantia nigra (SN) in patients with Parkinson's disease (PD) was demonstrated by transcranial ultrasound (TCS). In this study we set out to compare SN echogenicitiy with disease characteristics (time of onset, duration, toxin exposure) in a large patients sample. Patients' history and exposure to toxins were recorded from 112 PD patients who underwent a thorough neurological examination including assessment of disease stage according to Hoehn and Yahr and CURS (Columbia University Rating Scale). Personality was assessed according to the Freiburg Personality Inventory. In all patients the area of SN echogenicity was encircled and measured by TCS. All except 9 patients had hyperechogenic SN areas exceeding the mean plus standard deviation values of an age matched control group (0.19cm2). The age of disease onset was lower in patients who displayed an area of SN echogenicity above this value. The area of SN echogenicity was larger contralateral to the side with more severe symptoms. None of the other characteristics correlated with ultrasound findings. We conclude that SN hyperechogenicity is a typical finding in PD. The cause of hyperechogenicity is so far unknown. Investigation of the underlying reason might disclose a pathogenic factor in PD.

[1]  G Becker,et al.  Iron accumulation in the substantia nigra in rats visualized by ultrasound. , 1999, Ultrasound in medicine & biology.

[2]  G Becker,et al.  Vulnerability of the nigrostriatal system as detected by transcranial ultrasound , 1999, Neurology.

[3]  S. Fahn,et al.  Study of movement disorders and brain iron by MR. , 1987, AJR. American journal of roentgenology.

[4]  E. Ciceri,et al.  Magnetic resonance imaging in progressive supranuclear palsy and other parkinsonian disorders. , 1994, Journal of neural transmission. Supplementum.

[5]  T. Chase,et al.  Pathogenetic studies of motor fluctuations in Parkinson's disease. , 1988, Journal of neural transmission. Supplementum.

[6]  A. Seidler,et al.  Possible environmental, occupational, and other etiologic factors for Parkinson's disease , 1996, Neurology.

[7]  A. Crossman,et al.  A hypothesis on the pathophysiological mechanisms that underlie levodopa‐ or dopamine agonist‐induced dyskinesia in Parkinson's disease: Implications for future strategies in treatment , 1990, Movement disorders : official journal of the Movement Disorder Society.

[8]  M. Skalej,et al.  Magnetic resonance imaging–based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy , 1999, Annals of neurology.

[9]  P Riederer,et al.  Iron in the Parkinsonian substantia nigra. , 1997, Movement disorders : official journal of the Movement Disorder Society.

[10]  G Becker,et al.  Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography , 1995, Neurology.

[11]  P. Boesiger,et al.  T2 relaxation time in patients with Parkinson's disease , 1993, Neurology.

[12]  H. Schipper,et al.  A Cellular Stress Model for the Sequestration of Redox‐Active Glial Iron in the Aging and Degenerating Nervous System , 1995, Journal of neurochemistry.

[13]  J. Degroot,et al.  Magnetic resonance imaging of the midbrain in Parkinson's disease , 1986, Annals of neurology.

[14]  P. Riederer,et al.  Altered Brain Metabolism of Iron as a Cause of Neurodegenerative Diseases? , 1994, Journal of neurochemistry.

[15]  R. Ordidge,et al.  Increased iron‐related MRI contrast in the substantia nigra in Parkinson's disease , 1995, Neurology.

[16]  C. Marsden,et al.  Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy , 1995, Annals of neurology.

[17]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[18]  P D Griffiths,et al.  Iron in the basal ganglia in Parkinson's disease. An in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy. , 1999, Brain : a journal of neurology.

[19]  C. Marsden,et al.  Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental lewy body disease , 1992, Annals of neurology.

[20]  P Riederer,et al.  The neurotoxicity of iron and nitric oxide. Relevance to the etiology of Parkinson's disease. , 1993, Advances in neurology.

[21]  C. Marsden,et al.  Implications of alterations in trace element levels in brain in Parkinson's disease and other neurological disorders affecting the basal ganglia. , 1993, Advances in neurology.

[22]  C. Olanow Magnetic resonance imaging in parkinsonism. , 1992, Neurologic clinics.

[23]  Rolf-Dieter Stieglitz,et al.  Das Freiburger-Persönlichkeitsinventar (FPI) , 2002 .

[24]  A. Horsman,et al.  Unchanged basal ganglia N‐acetylaspartate and glutamate in idiopathic Parkinson's disease measured by proton magnetic resonance spectroscopy , 1997, Movement disorders : official journal of the Movement Disorder Society.

[25]  H. Möller,et al.  Localized proton NMR spectroscopy in the striatum of patients with idiopathic parkinson's disease: a multicenter pilot study , 1995 .

[26]  N. Reynolds,et al.  Qualitative Assessment of Parkinson's Disease: Study of Reliability and Data Reduction with an Abbreviated Columbia Scale , 1985, Clinical neuropharmacology.

[27]  Francesco Federico,et al.  Proton magnetic resonance spectroscopy in parkinson's disease and atypical parkinsonian disorders , 1997 .